Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial
European Journal of Cancer2019Vol. 110, pp. 32–41
Citations Over TimeTop 10% of 2019 papers
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, Sara Lonardi, P Buccianti, A. Sainato, Lorenzo Marcucci, Angelo Martignetti, Emanuele Damiano Luca Urso, Maura Castagna, Gabriella Fontanini, Francesca Bergamo, Gianna Musettini, Lucio Urbani, Elisa Sensi, Riccardo Balestri, S. Montrone, Francesco Pasqualetti, Chiara Cremolini, Antonello Di Paolo, Vittorina Zagonel, Alfredo Falcone
Related Papers
- → Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials(2010)90 cited
- → Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials(2017)8 cited
- → An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT](2013)18 cited
- → Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer(2012)8 cited
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)